These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16054748)

  • 1. Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project.
    van Gils MP; Stenman UH; Schalken JA; Schröder FH; Luider TM; Lilja H; Bjartell A; Hamdy FC; Pettersson KS; Bischoff R; Takalo H; Nilsson O; Mulders PF; Bangma CH
    Eur Urol; 2005 Dec; 48(6):1031-41. PubMed ID: 16054748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen kinetics in localized and advanced prostate cancer.
    Fitzpatrick JM; Banu E; Oudard S
    BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
    Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer.
    Stephan C; Jung K; Nakamura T; Yousef GM; Kristiansen G; Diamandis EP
    Int J Urol; 2006 Mar; 13(3):238-43. PubMed ID: 16643616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [PSA related screening of prostate cancer. Panic or improvement?].
    Fornara P; Jurczok A
    Aktuelle Urol; 2004 Feb; 35(1):43-8. PubMed ID: 14997414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
    Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
    Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of serum and urinary myeloid related protein-14 as a marker for early detection of prostate cancer.
    Müller H; Haug U; Rothenbacher D; Stegmaier C; Brenner H
    J Urol; 2008 Oct; 180(4):1309-12; discussion 1312-3. PubMed ID: 18707695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate specific antigen: an updated review.
    So A; Goldenberg L; Gleave ME
    Can J Urol; 2003 Dec; 10(6):2040-50. PubMed ID: 14704108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early diagnosis of prostate cancer: the continuing debate on the impact on mortality.
    Höltl W; Lunglmayr G
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):440-1. PubMed ID: 16091868
    [No Abstract]   [Full Text] [Related]  

  • 11. Beyond prostate-specific antigen: alternate serum markers.
    Ramírez ML; Nelson EC; Evans CP
    Prostate Cancer Prostatic Dis; 2008; 11(3):216-29. PubMed ID: 18227856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSA and other tissue kallikreins for prostate cancer detection.
    Stephan C; Jung K; Lein M; Diamandis EP
    Eur J Cancer; 2007 Sep; 43(13):1918-26. PubMed ID: 17689069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Markers for diagnosis, prediction and prognosis of prostate cancer].
    Taskén KA; Angelsen A; Svindland A; Eide T; Berge V; Wahlquist R; Karlsen S
    Tidsskr Nor Laegeforen; 2005 Dec; 125(23):3279-82. PubMed ID: 16327854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New circulating biomarkers for prostate cancer.
    Bensalah K; Lotan Y; Karam JA; Shariat SF
    Prostate Cancer Prostatic Dis; 2008; 11(2):112-20. PubMed ID: 17998918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen doubling time as a prognostic marker in prostate cancer.
    Eastham JA
    Nat Clin Pract Urol; 2005 Oct; 2(10):482-91. PubMed ID: 16474622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are multiple markers the future of prostate cancer diagnostics?
    Mikolajczyk SD; Song Y; Wong JR; Matson RS; Rittenhouse HG
    Clin Biochem; 2004 Jul; 37(7):519-28. PubMed ID: 15234233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
    Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
    Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The search for better markers for prostate cancer than prostate-specific antigen].
    Schenk-Braat EA; Bangma CH
    Ned Tijdschr Geneeskd; 2006 Jun; 150(23):1286-90. PubMed ID: 16821452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood biomarkers for prostate cancer detection and prognosis.
    Shariat SF; Karam JA; Roehrborn CG
    Future Oncol; 2007 Aug; 3(4):449-61. PubMed ID: 17661720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of progress in early diagnosis of bladder cancer.
    Araki M; Nieder AM; Manoharan M; Yang Y; Soloway MS
    Urology; 2007 Feb; 69(2):270-4. PubMed ID: 17320662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.